ChemPartner PharmaTech Co., Ltd. — Investor Relations & Filings
ChemPartner PharmaTech Co., Ltd. is a global research and development organization providing comprehensive drug discovery and development services. Operating as a Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO), the company supports pharmaceutical and biotechnology clients through an integrated service platform. Core capabilities include medicinal chemistry, biology, pharmacology, drug metabolism and pharmacokinetics (DMPK), and toxicology. The organization also offers specialized expertise in biologics discovery, protein engineering, and antibody development. ChemPartner facilitates the transition from early-stage research to clinical development through its pharmaceutical development and manufacturing capabilities, utilizing advanced technology to accelerate the discovery and production of novel therapeutic agents.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 关于召开2026年第一次临时股东会的通知 | 2026-02-27 | Chinese | |
| 睿智医药2025年限制性股票激励计划（草案修订稿）摘要 | 2026-02-27 | Chinese | |
| 北京市竞天公诚律师事务所上海分所关于睿智医药科技股份有限公司2025年限制性股票激励计划调整事项之法律意见书 | 2026-02-27 | Chinese | |
| 睿智医药2025年限制性股票激励计划实施考核管理办法（修订稿） | 2026-02-27 | Chinese | |
| 董事、高级管理人员薪酬管理制度 | 2026-02-27 | Chinese | |
| 睿智医药2025年限制性股票激励计划（草案修订稿） | 2026-02-27 | Chinese |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
12 filings
| |||||
| 36046783 | 关于召开2026年第一次临时股东会的通知 | 2026-02-27 | Chinese | ||
| 36046782 | 睿智医药2025年限制性股票激励计划（草案修订稿）摘要 | 2026-02-27 | Chinese | ||
| 36046774 | 北京市竞天公诚律师事务所上海分所关于睿智医药科技股份有限公司2025年限制性股票激励计划调整事项之法律意见书 | 2026-02-27 | Chinese | ||
| 36046773 | 睿智医药2025年限制性股票激励计划实施考核管理办法（修订稿） | 2026-02-27 | Chinese | ||
| 36046772 | 董事、高级管理人员薪酬管理制度 | 2026-02-27 | Chinese | ||
| 36046771 | 睿智医药2025年限制性股票激励计划（草案修订稿） | 2026-02-27 | Chinese | ||
| 36046766 | 简式权益变动报告书（梁玉凤） | 2026-02-09 | Chinese | ||
| 36046757 | 关于持股5%以上股东减持至5%以下暨权益变动的提示性公告 | 2026-02-09 | Chinese | ||
| 36046746 | 简式权益变动报告书（于显文） | 2026-02-09 | Chinese | ||
| 36046743 | 2025年度业绩预告 | 2026-01-30 | Chinese | ||
| 36046735 | 关于担保进展的公告 | 2026-01-22 | Chinese | ||
| 36046723 | 关于持股5%以上股东减持股份的预披露公告 | 2026-01-15 | Chinese | ||
|
2025
3 filings
| |||||
| 36046718 | 关于关联方对全资子公司增资进展暨完成工商登记的公告 | 2025-12-22 | Chinese | ||
| 36046704 | 关于担保进展的公告 | 2025-12-19 | Chinese | ||
| 36046694 | 关于高级管理人员辞职的公告 | 2025-12-12 | Chinese | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Alteogen Inc.
Biopharmaceutical firm developing biologics with proprietar…
|
196170 | KR | Professional, scientific and te… |
|
ALTERITY THERAPEUTICS LIMITED
Clinical-stage developer of disease-modifying therapies for…
|
ATH | AU | Professional, scientific and te… |
|
AlzeCure Pharma
Develops therapies for severe diseases, focusing on Alzheim…
|
ALZCUR | SE | Professional, scientific and te… |
|
AMPLIA THERAPEUTICS LIMITED
Clinical-stage developer of FAK inhibitors for solid tumors…
|
ATX | AU | Professional, scientific and te… |
|
ANAPTYSBIO, INC
Clinical-stage biotech developing immunology therapeutics f…
|
ANAB | US | Professional, scientific and te… |
|
ANATARA LIFESCIENCES LTD
Develops non-antibiotic gastrointestinal health solutions f…
|
ANR | AU | Professional, scientific and te… |
|
AngioLab, Inc.
Develops angiogenesis inhibitors for pharmaceuticals and he…
|
251280 | KR | Professional, scientific and te… |
|
Anhui Wanbang Pharmaceutical Technology Co.,Ltd.
Pharmaceutical CRO specializing in clinical trials, BE stud…
|
301520 | CN | Professional, scientific and te… |
|
Anixa Biosciences Inc
A clinical-stage biotech developing therapies and vaccines …
|
ANIX | US | Professional, scientific and te… |
|
Annovis Bio, Inc.
A clinical-stage drug platform company developing therapies…
|
ANVS | US | Professional, scientific and te… |
ChemPartner PharmaTech Co., Ltd. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/55161/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=55161 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=55161 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=55161 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 55161}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for ChemPartner PharmaTech Co., Ltd. (id: 55161)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.